Premium
Improved treatment of paget's disease with dimethylaminohydroxypropylidene bisphosphonate
Author(s) -
Schweitzer Dave H.,
Zwinderman Aeilko H.,
Vermeij Pieter,
Bijvoet Olav L.M.,
Papapoulos Socrates E.
Publication year - 1993
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650080208
Subject(s) - bisphosphonate , medicine , paget's disease of bone , surgery , complete remission , disease , gastroenterology , chemotherapy , osteoporosis
A group of 89 patients with Paget's disease of bone were treated with different intravenous or oral doses of the nitrogen‐containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate (dimethyl‐APD). Biochemical remission was obtained in 82% of treatments, and in the rest a clear response was found. Oral dimethyl‐APD was well tolerated, and a dose of 200 mg/day for 10 days was sufficient to induce remission in the majority of patients. The remission probability was 3 months for 50% of patients, and the recurrence‐free period was 27 months. The remission probability as well as the recurrence‐free period did not differ among oral and intravenous treatments or among patients who had never been treated with nitrogen‐containing bisphosphonates and those who had received pamidronate in the past and were treated for a recurrence of the disease. Dimethyl‐APD is a very effective bisphosphonate devoid of side effects, which given for a short period can induce long‐lasting remissions in patients with Paget's disease of bone.